Arvinas, Inc. (ARVN)
Arvinas, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New Haven, CT, US. The stock last traded at $7.59, down 2.57% on the session, giving a market capitalisation of $489.7M. On trailing twelve-month figures it carries a trailing P/E of 39.95, a net margin of 2.9%. Its beta of 1.76 implies it has historically moved more than the broad market.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Arvinas, Inc. is most often compared with the following Healthcare names: